Aintzane Zabaleta

2.0k total citations
40 papers, 914 citations indexed

About

Aintzane Zabaleta is a scholar working on Immunology, Molecular Biology and Hematology. According to data from OpenAlex, Aintzane Zabaleta has authored 40 papers receiving a total of 914 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Immunology, 13 papers in Molecular Biology and 12 papers in Hematology. Recurrent topics in Aintzane Zabaleta's work include Immunotherapy and Immune Responses (11 papers), Multiple Myeloma Research and Treatments (10 papers) and Immune Cell Function and Interaction (10 papers). Aintzane Zabaleta is often cited by papers focused on Immunotherapy and Immune Responses (11 papers), Multiple Myeloma Research and Treatments (10 papers) and Immune Cell Function and Interaction (10 papers). Aintzane Zabaleta collaborates with scholars based in Spain, United Kingdom and United States. Aintzane Zabaleta's co-authors include Jesús Prìeto, Bruno Paiva, Juan José Lasarte, Pablo Sarobe, Juan C. Mareque‐Rivas, Francisco Borrás‐Cuesta, Ane Ruiz‐de‐Angulo, Jordi Llop, Laura Arribillaga and Ignacio Melero and has published in prestigious journals such as Journal of Clinical Oncology, Blood and ACS Nano.

In The Last Decade

Aintzane Zabaleta

37 papers receiving 898 citations

Peers

Countries citing papers authored by Aintzane Zabaleta

Since Specialization

Citations

This map shows the geographic impact of Aintzane Zabaleta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aintzane Zabaleta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aintzane Zabaleta more than expected).

Fields of papers citing papers by Aintzane Zabaleta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aintzane Zabaleta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aintzane Zabaleta. The network helps show where Aintzane Zabaleta may publish in the future.

Co-authorship network of co-authors of Aintzane Zabaleta

This figure shows the co-authorship network connecting the top 25 collaborators of Aintzane Zabaleta. A scholar is included among the top collaborators of Aintzane Zabaleta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aintzane Zabaleta. Aintzane Zabaleta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The origin of autoimmune diseases: is there a role for ancestral HLA-II haplotypes in immune hyperactivity 2025 ·Frontiers in Immunology ·(unknown), Bruno Paiva, Aintzane Zabaleta	0
2	Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia 2024 ·Blood Advances ·Esperanza Martín‐Sánchez, Laura Blanco, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi van de Velde, Tomáš Jelı́nek, (unknown), Felipe Prósper, Jesús F. San Miguel, Ana Alfonso Piérola, Juan Bergua, Rebeca Rodríguez‐Veiga, Susana Vives, David Martínez‐Cuadrón, Pau Montesinos, Bruno Paiva, Aintzane Zabaleta	5
3	Deep Characterization of Immune Dysfunction in Patients with Multiple Myeloma (MM) and Identification of Cellular Biomarkers for Tailored Vaccination Strategies 2023 ·Blood ·Esperanza Martín‐Sánchez, (unknown), (unknown), (unknown), Aintzane Zabaleta, Catarina Maia, Laura Blanco, (unknown), Carlos Grande, (unknown), (unknown), (unknown), Ernesto Pérez Persona, (unknown), (unknown), Carlos Panizo, Felipe Prósper, Jesús F. San Miguel, Paula Rodríguez‐Otero, Bruno Paiva	0
4	Clinical Significance of Measurable Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor (CAR) T Cells and T-Cell Engagers (TCE) 2023 ·Blood ·Aintzane Zabaleta, Noemí Puig, (unknown), José J. Pérez, Cristina Moreno, (unknown), Paula Rodríguez‐Otero, Verónica González‐Calle, Lucía López‐Corral, (unknown), (unknown), Fátima Mirás, José María Sánchez‐Pina, (unknown), Joaquín Martínez‐López, María‐Victoria Mateos, Jesús F. San Miguel, Bruno Paiva	4
5	Epstein–Barr virus-acquired immunodeficiency in myalgic encephalomyelitis—Is it present in long COVID? 2023 ·Journal of Translational Medicine ·(unknown), Bruno Paiva, Aintzane Zabaleta	13
6	A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML) 2023 ·Blood ·Aintzane Zabaleta, Esperanza Martín‐Sánchez, (unknown), Peter Kim, Kamlesh Bisht, Hongfang Wang, (unknown), Tomáš Jelı́nek, (unknown), Felipe Prósper, Jesús F. San Miguel, David Martínez‐Cuadrón, Pau Montesinos, Bruno Paiva	1
7	Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome 2021 ·Frontiers in Immunology ·(unknown), Bruno Paiva, (unknown), (unknown), Aintzane Zabaleta	61
8	The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma 2019 ·Clinical Cancer Research ·Laura Moreno, Cristina Pérez, Aintzane Zabaleta, Irene Manrique, Diego Alignani, Daniel Ajona, Laura Blanco, Marta Lasa, Patricia Maiso, Idoia Rodríguez, Sonia Gárate, Tomáš Jelı́nek, Víctor Segura, Cristina Moreno, Juana Merino, Paula Rodríguez‐Otero, Carlos Panizo, Felipe Prósper, Jesús F. San Miguel, Bruno Paiva	148
9	Immunophenotypic Pattern of De Novo Malignancy After Liver Transplantation 2019 ·Transplantation Proceedings ·(unknown), Aintzane Zabaleta, (unknown), (unknown), Leire Burgos, Bruno Paiva, J.I. Herrero	2
10	Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles 2018 ·Biomaterials ·Ana Bocanegra, Ane Ruiz‐de‐Angulo, Aintzane Zabaleta, (unknown), (unknown), María Jesús García-Granda, Daniel Padró, Jordi Llop, Blanca Arnáiz, María Gato, David Escors, Juan C. Mareque‐Rivas	86
11	Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy 2018 ·Journal of Proteomics ·(unknown), Aintzane Zabaleta, Marc García-Moure, Marta M. Alonso, Joaquín Fernández‐Irigoyen, Enrique Santamaría	11
12	Pre-Clinical Efficacy of the Anti-CD38 Monoclonal Antibody (mAb) Isatuximab in Acute Myeloid Leukemia (AML) 2017 ·Blood ·Tomáš Jelı́nek, Aintzane Zabaleta, Cristina Pérez, Daniel Ajona, Diego Alignani, Idoia Rodríguez, Sonia Gárate, Sarai Sarvide, Marta Lasa, Patricia Maiso, Felipe Prósper, Roman Hájek, Jesús F. San Miguel, Bruno Paiva	3
13	Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection 2015 ·Molecular Therapy — Methods & Clinical Development ·Aintzane Zabaleta, Delia D’Avola, (unknown), Diana Llópiz, Leyre Silva, Lorea Villanueva, José Ignacio Riezu‐Boj, Esther Larrea, Alexander Pereboev, Juan José Lasarte, Iago Rodríguez–Lago, Mercedes Iñarrairaegui, Bruno Sangro, Jesús Prìeto, Pablo Sarobe	16
14	Helper cell-independent antitumor activity of potent CD8⁺T cell epitope peptide vaccines is dependent upon CD40L 2013 ·OncoImmunology ·Diana Llópiz, Eduardo Huarte, Marta Ruiz, Jaione Bezunartea, Virginia Belsúe, Aintzane Zabaleta, Juan José Lasarte, Jesús Prìeto, Francisco Borrás‐Cuesta, Pablo Sarobe	3
15	Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells 2011 ·Hepatology ·(unknown), Alexander Pereboev, Leyre Silva, Aintzane Zabaleta, José Ignacio Riezu‐Boj, Marta Bes, María Cubero, Francisco Borrás‐Cuesta, Juan José Lasarte, Juan Ignacio Esteban, Jesús Prìeto, Pablo Sarobe	22
16	Early Changes in Interferon Signaling Define Natural Killer Cell Response and Refractoriness to Interferon–Based Therapy of Hepatitis C Patients 2011 ·Hepatology ·Birgit Edlich, Golo Ahlenstiel, Aintzane Zabaleta, (unknown), Mazen Noureddin, Elisavet Serti, Jordan J. Feld, Jake T. Liang, Yaron Rotman, Barbara Rehermann	90
17	Monocyte‐derived dendritic cells from HCV‐infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C) 2008 ·Journal of Viral Hepatitis ·(unknown), Aintzane Zabaleta, Leyre Silva, Nancy Díaz‐Valdés, José Ignacio Riezu‐Boj, Juan José Lasarte, Francisco Borrás‐Cuesta, M.P. Civeira, Jesús Prìeto, Pablo Sarobe	11
18	Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40 2007 ·Antiviral Research ·Aintzane Zabaleta, Laura Arribillaga, Diana Llópiz, Javier Dotor, Juan José Lasarte, Jesús Prìeto, Francisco Borrás‐Cuesta, Juan Ignacio Esteban, Josep Quer, (unknown)	12
19	Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects 2007 ·Cancer Immunology Immunotherapy ·Diana Llópiz, Javier Dotor, Aintzane Zabaleta, Juan José Lasarte, Jesús Prìeto, Francisco Borrás‐Cuesta, Pablo Sarobe	42
20	Engineered promiscuous T helper peptides for the induction of immune responses 2006 ·Molecular Immunology ·Marta Ruiz, Diana Llópiz, Aintzane Zabaleta, Juan José Lasarte, Francisco Borrás‐Cuesta, Pablo Sarobe	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact